KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBITDA Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of EBITDA Margin data on record, last reported at 32.21% in Q2 2025.

  • For Q2 2025, EBITDA Margin rose 3051.0% year-over-year to 32.21%; the TTM value through Jun 2025 reached 51.42%, up 4767.0%, while the annual FY2024 figure was 191.27%, 23417.0% up from the prior year.
  • EBITDA Margin reached 32.21% in Q2 2025 per SRPT's latest filing, up from 15.61% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 32.21% in Q2 2025 and bottomed at 1148.96% in Q3 2022.
  • Average EBITDA Margin over 5 years is 119.99%, with a median of 49.61% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -112834bps in 2022, then soared 96883bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 108.94% in 2021, then soared by 42bps to 63.66% in 2022, then surged by 116bps to 10.19% in 2023, then tumbled by -253bps to 15.61% in 2024, then soared by 306bps to 32.21% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 32.21% in Q2 2025, 15.61% in Q4 2024, and 3.37% in Q3 2024.